3002.13.00.90/Unmixed Monoclonal Antibody Bevacizumab/Canada

Unmixed Monoclonal Antibody Bevacizumab from Canada

Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) for therapeutic use in cancer treatment. It falls under HTS 3002.13.0090 as an unmixed immunological product not put up in measured doses or retail packaging, directly involved in regulating immunological processes. This classification applies to bulk biotech-derived antibodies for further pharmaceutical processing.

Duty Rate — Canada → United States

100%

Rate breakdown

9903.04.60100%Except as provided in heading 9903.04.61, patented pharmaceutical articles as provided for in subdivisions (c) and (d) of U.S. note 40 to this subchapter

9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter

9903.05.900%Articles of aluminum, of steel or of copper or derivative aluminum or steel articles; passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; parts of passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; medium- and heavy-duty vehicles; parts of medium- and heavy-duty vehicles; wood products; patented pharmaceutical articles; and semiconductor articles, as provided in subdivision (f) of U.S. note 52 to this subchapter

Calculate with your customs value Verify classification with AI

Import Tips

• Verify FDA biologics license and provide certificates of analysis confirming purity and biotech origin to avoid misclassification as Chapter 29 chemicals

• Ensure cold chain documentation (2-8°C) during import to maintain product integrity, as deviations can lead to customs holds

• Declare exact concentration and absence of excipients to confirm 'unmixed' status; common pitfall is classifying diluted solutions under 3002.14